Skip to main content
. Author manuscript; available in PMC: 2014 Feb 8.
Published in final edited form as: Int J Tuberc Lung Dis. 2013 Apr;17(4):552–558. doi: 10.5588/ijtld.12.0627

Figure 3. Three-way Sensitivity Analysis: Effect of Assay Specificity, TB prevalence, and Life Expectancy after TB cure in South Africa.

Figure 3

Cost-utility of lateral-flow urine LAM, according to specificity, TB prevalence, and life expectancy after TB cure in South Africa. Grey shading indicates that the existing diagnostic strategy (without Xpert MTB/RIF) would be preferred at a willingness to pay (WTP) of $7,275, while white shading indicates that addition of lateral-flow urine LAM would be preferred at this WTP threshold. Thus, for example, assuming a life expectancy of 1.5 years and assay specificity of 95%, lateral-flow urine LAM would be the preferred testing strategy in South Africa if deployed in populations with a probability of finding active TB that is greater than 5% (panel A, transition from white to grey).